Related Experiment Video
Updated: Sep 2, 2025

Author Spotlight: Evaluating Therapeutic Strategies to Enhance Liver Regeneration
Published on: May 24, 2024
Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis
Benjamin Schulte1, Tammo L Tergast, Marie Griemsmann
1Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School; Center for Individualized Infection Medicine (CiiM), Hannover; German Center for Infection Research (DZIF), German Liver Foundation, HepNet, Hannover; Twincore, Center for Experimental and Clinical Infection Research, Hannover; German Center for Infection Research (DZIF), Hannover-Braunschweig; Institute for Clinical Pharmacology, Hannover Medical School.
Metamizole use in patients with decompensated cirrhosis increases the risk of acute renal failure (ARF) and lowers survival rates. High doses of metamizole are particularly concerning for these vulnerable patients.
Area of Science:
- Hepatology
- Nephrology
- Pharmacology
Background:
- Decompensated hepatic cirrhosis patients face increased acute renal failure (ARF) risk.
- Cyclooxygenase (COX) inhibitors are generally contraindicated.
- Metamizole's safety in this population is not well-established.
Purpose of the Study:
- To investigate the effect of metamizole on ARF risk in decompensated cirrhosis patients.
- To assess metamizole's impact on patient survival.
- To evaluate dose-dependent effects of metamizole on ARF.
Main Methods:
- Retrospective exploratory cohort study.
- Prospective registry validation.
- Analysis of metamizole use, ARF incidence, and mortality.
Main Results:
- Metamizole use was independently associated with increased ARF (HR: 2.2) and severe ARF (HR: 2.8).
- Higher metamizole doses correlated with increased ARF risk (HR: 1.038).
- Metamizole use was linked to lower 28-day survival (HR: 2.6) and higher ARF rates compared to opioids.
Conclusions:
- Metamizole therapy poses a significant risk of ARF in decompensated cirrhosis.
- High-dose metamizole use requires extreme caution in this patient group.
- Further research into safer analgesia options is warranted.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Drug Metabolism: Phase II Reactions
Drug Metabolism: Phase I Reactions
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

